스몰랩

비상장계속사업자

Smalllab.Co.,Ltd

이정규

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

스몰랩

Business Reg. No. 1058723084 · CEO 이정규

I.Investment Overview

Target스몰랩 (1058723084)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명스몰랩
영문명Smalllab.Co.,Ltd
대표자이정규
사업자등록번호1058723084
법인등록번호1101113949504
설립일2008.08.07

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW64.52020137.2202159.42022110.520241452025
영업이익100M KRW4.3202020.42021-13.220227.4202416.32025
순이익100M KRW7.9202019.32021-8.2202214.320244.52025
Item20252024202220212020
자산총계147.9억원126.4억원119.8억원124.1억원73.7억원
부채총계73.5억원90.6억원95.7억원95.4억원32.5억원
자본총계74.5억원35.8억원24.1억원28.7억원41.3억원
매출액145억원110.5억원59.4억원137.2억원64.5억원
영업이익16.3억원7.4억원-13.2억원20.4억원4.3억원
순이익4.5억원14.3억원-8.2억원19.3억원7.9억원

VI.Financial Ratios

FY2025 basis

11.23%

영업이익률

3.12%

순이익률

3.06%

ROA

6.08%

ROE

98.62%

부채비율

50.35%

자기자본비율

VII.R&D Activity

Fields 보건의료 > 신약·의약품개발 · 과학기술과 인문사회 > 기타 과학기술과인문사회 · 화공 > 정밀화학

Keywords 마이크로니들, 인공지능, 경피약물전달, 피부질환, 약물전달

YearProjectsPapersPatents
2026200
2025200
2024301
2023101
2022000
2021101
2020200
2019100
2017001
2012002
2011100
2010100

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.